CM336
Stories
-
Keymed registers Phase 3 trial of CM336+CM313 in relapsed multiple myeloma
The study, led by Keymed Biosciences Co.Ltd, plans to enroll 320 participants and start in December 2026. It compares CM336+CM313 with Daratumumab+Pomalidomide+Dexamethasone in patients who have received 1 to 3 prior lines of therapy.